FIREFLY NEUROSCIENCE, INC.

Firefly Neuroscience, Inc. announced the mutual termination of a securities purchase agreement with an accredited investor. The agreement, originally disclosed on May 12, 2026, involved the potential sale of up to 666,667 units at $1.50 each, for aggregate gross proceeds of up to $1,000,000. The termination was effective June 25, 2026.

Firefly Neuroscience, Inc. announced a change in the role and classification of Gil Issachar. Formerly the Chief Technology Officer, Issachar now serves as the Head of AI and Neuroscience under an employment agreement with Deel Innovation Ltd. As a result of this role change, the board of directors determined that Issachar is no longer classified as a Section 16 officer or executive officer of the Company, effective June 18, 2026.

Firefly Neuroscience, Inc. announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (PTSD) using brain scans collected on its FDA-510(k)-cleared Evoke System. This discovery stems partly from Firefly's partnership with the U.S. Department of War (DoW) and leverages NVIDIA L40S GPU-accelerated infrastructure. The company believes this positions it uniquely with both a government brain health partnership and an identified neural signal marker for PTSD, potentially opening commercial pathways in defense health, pharma, and clinical psychiatry.

Firefly Neuroscience, Inc. reported a significant improvement in its financial performance for the first quarter ended March 31, 2026. Revenue surged to $485,000 from $43,000 in the prior year, while net loss narrowed substantially to $(2.0) million from $(12.9) million. Despite these improvements, the company continues to face a going concern risk due to an accumulated deficit and negative operating cash flow, necessitating ongoing capital raises. The company successfully raised $2.39 million in Q1 2026 and an additional $8.0 million post-quarter through private placements and warrant exercises.

Firefly Neuroscience, Inc. has entered into a securities purchase agreement to issue and sell up to 666,667 units to an accredited investor, aiming to raise up to $1,000,000 in gross proceeds. Each unit, priced at $1.50, includes one share of common stock and two common stock purchase warrants with exercise prices of $1.88 and $2.50. The closing of this offering is contingent upon obtaining shareholder approval for the warrant exercise and the effectiveness of a resale registration statement, which the company is required to file by May 21, 2026.

Firefly Neuroscience, Inc. completed an additional closing of its Securities Purchase Agreement, raising $8,000,000. The company issued 5,333,333 units to an accredited investor at a price of $1.50 per unit, consistent with the terms disclosed in a prior filing. Concurrently, an Amended and Restated Lock-Up Agreement was executed, restricting the transfer of Lock-Up Securities until May 16, 2026.

Firefly Neuroscience announced a major operational and commercial milestone, surpassing 200,000 EEG/ERP brain scans. The company reported sequential scan volume growth of 5%, 11%, 15%, and 17% over the past four quarters, driven by the acquisition of Evoke Neuroscience and internal growth initiatives. This achievement is expected to enable new breakthroughs in cognitive brain biomarker discovery and supports Firefly's goal of launching the world's first EEG/ERP-based foundation model of the human brain, utilizing NVIDIA L40S GPU acceleration.